Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

redictive value, PPV) than patients in the Pegasys combination arm (92 vs. 87 vs. 80 percent, and 81 vs. 83 vs. 74 percent, respectively).(5)

-- Relapse after the end of treatment was lower for patients in the PEGINTRON combination therapy arms compared to patients receiving Pegasys and Copegus (24 vs. 20 vs. 32 percent, respectively). In a multivariate logistic regression analysis, among the factors significantly affecting relapse were: baseline viral load greater than 600,000 IU/mL vs. less than or equal to 600,000 IU/mL (p-value less than 0.001); age greater than 40 vs. less than or equal to 40 (p-value less than 0.001); fibrosis F3/4 vs. F0/1/2 (p-value equal to 0.001); Pegasys regimen vs. PEGINTRON 1.0 mcg regimen (p-value less than 0.001); glucose fasting greater than or equal to 5.6 vs. less than 5.6 (p-value equal to 0.002); steatosis 0 percent vs. greater than 0 percent (p-value equal to 0.002); ALT normal vs. elevated (p-value equal to 0.008); and Pegasys regimen vs. PEGINTRON 1.5 mcg regimen (p-value equal to 0.012).

-- End of treatment response was higher in the Pegasys combination arm (53 vs. 49 vs. 64 percent, respectively).

-- Ribavirin dose: One of the key questions of the study has been whether the protocol-assigned ribavirin dose regimen or the protocol-specified dose reduction schedule disadvantaged patients in any of the treatment arms, particularly in the Pegasys combination arm. However, the final results of IDEAL showed that the majority of patients in the Pegasys therapy arm received a higher ribavirin dose over the duration of the study, including patients with ribavirin dose reductions or discontinuations, based on the actual median ribavirin dose received (mg/kg/day), regardless of treatment outcome (SVR, relapsers and nonresponders) [p-value less than 0.001 for ribavirin dose received in the PEGINTRON 1.5 mcg arm vs. Pegasys arm and p-value less than or equal to 0.001 for ribavirin dose received in the PEGINTRON 1.0 a
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 Cambrex Corporation (NYSE: CBM ) ... Highlights , Sales increased 18% ... excluding foreign currency impact, driven by Innovator products and Controlled ... million in the first quarter of 2014. , GAAP ... the first quarter last year and Adjusted Diluted EPS was ...
(Date:4/30/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a ... reported financial results for the fourth quarter and fiscal ... and fiscal 2015 overview: , Revenues from continuing ... 33% over last year,s comparable quarter, and $202.6 million ... EPS of $0.50 for the fourth quarter, up 194% ...
(Date:4/30/2015)... 2015  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, May 7, 2015 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
(Date:5/1/2015)... Providenciales, Turks and Caicos Islands, BWI (PRWEB) May 02, ... has a new website! It is http://www.thevenetiangracebay.com ... resort itself, and it incorporates the stunning white and ... "According to a study of Google, sixty seven percent ... process. The study showed that smartphones were used ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... May 01, 2015 The Workgroup ... nonprofit authority on the use of health IT to ... key contributing resource to the United States Government Accountability ... electronically readable cards in Medicare. The report, “ Potential ... ” was released to the public on Apr. 24, ...
(Date:5/1/2015)... 2015 It’s raining bills on Capitol Hill ... to expand federal support for telemedicine. , “Such ... been working with Congress,” said Jonathan Linkous, CEO of the ... nation is poised to embrace the use of telecommunications in ... in fulfilling ATA’s mission to improve quality, access, equity and ...
Breaking Medicine News(10 mins):Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2
... Lancet (vol. 370, 11 August 2007) could lead to a ... It states that magnetic resonance imaging (MRI) is substantially more ... cancer . Up to now MRI was thought to be ... situ (DCIS) . Researchers at the University of Bonn have ...
... increase according to stage of disease, a new study ... CANCER, a peer-reviewed journal of the American Cancer Society, ... each stage, African American women had larger tumors and ... to nearby lymph nodes. After controlling for those clinical ...
... Today’s report from the Food and Drug Administration (FDA) ... forward in the agency’s effort to tackle the new ... The Task Force is clear and candid in acknowledging ... product category FDA regulates—from pharmaceuticals and devices to cosmetics ...
... by researchers at the University of Southern California, has brought ... the genetic changes that enable tumours to evade the body's ... breast and colorectal cancers, are significant to the field of ... tests and treatment for cancers. ,"The implication is ...
... baby to be produced from an egg, that was developed in ... ,The news provides hope for women who have ... help egg maturation in the ovaries themselves. ,The baby ... Canada after work at the McGill Reproductive Centre in Montreal. The ...
... community is struggling to come to terms with the aftermath of ... are emerging. ,An al-Qaeda leader in Iraq may ... when he reportedly told a British cleric in Baghdad that "those ... ,The cleric passed on details of the warning, but ...
Cached Medicine News:Health News:MRI finds breast cancer before it becomes dangerous 2Health News:MRI finds breast cancer before it becomes dangerous 3Health News:Survival differences by race most apparent in advanced stages of breast cancer 2Health News:Researchers Discover How Cancer Evades the Immune System 2Health News:First Baby Born from Eggs Matured and Frozen in the Lab 2Health News:Those Who Cure can Kill Dire Prophesy of the doctors Plot 2
... Techno-Aide provides the highest level of ... quality lead protective eyewear. Consistent ... tolerance allowed. Mfg supervised by Licensed ... lens meet or exceed standards for ...
... has a unique wrap around design which ... brow for optimum coverage. The ratchet ... out, up and down for a comfortable ... similar to the Model #67, however, the ...
A soft vinyl goggle with limited splash protection due to its contoured facial fit. With leaded side shields added for increased scatter radiation protection. The mask easily fits over existing glass...
... The wrap frame is constructed of extremely ... minimizing potential breakage. The molded wrap ... full saddle bridge to distribute weight evenly ... vision with leaded glass side shields. ...
Medicine Products: